Benoxaprofen in treatment of systemic sclerosis.
Ten patients with systemic sclerosis were treated with benoxaprofen, a potent lipoxygenase inhibitor, for a period of 6 months. In an attempt to evaluate the efficacy a number of physical disease parameters were followed during the trial. None of these parameters revealed any significant differences. There was, however, a trend for a change towards normalisation of a defect monocyte chemotaxis. In view of the slow and progressive nature of systemic sclerosis the present study leaves undetermined whether benoxaprofen exerts a beneficial effect on systemic sclerosis.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D016859:Lipoxygenase Inhibitors; D008297:Male; D008875:Middle Aged; D011422:Propionates / Q000009:adverse effects / Q000627:therapeutic use*; D012595:Scleroderma, Systemic / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D016859:Lipoxygenase Inhibitors; D011422:Propionates; C011677:benoxaprofen